If Alecensa (Alectinib) Isn't Approved by Cigna in New York: Formulary Alternatives & Exception Paths
Answer Box: When Cigna Denies Alecensa (Alectinib) in New York
If Cigna denies Alecensa (alectinib) for ALK-positive NSCLC, you have three main paths: try formulary alternatives (crizotinib, brigatinib), request a formulary exception with clinical evidence, or appeal through New York's external review process. Most denials stem from missing